

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7147462

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SEBASTIAN SCHAEFER	11/21/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NATIONAL HEART CENTRE OF SINGAPORE
<b>Street Address:</b>	31 THIRD HOSPITAL AVENUE
<b>Internal Address:</b>	#03-03 BOWYER BLOCK C
<b>City:</b>	SINGAPORE
<b>State/Country:</b>	SINGAPORE
<b>Postal Code:</b>	168753
<b>Name:</b>	NATIONAL UNIVERSITY OF SINGAPORE
<b>Street Address:</b>	21 LOWER KENT RIDGE ROAD
<b>City:</b>	SINGAPORE
<b>State/Country:</b>	SINGAPORE
<b>Postal Code:</b>	119077
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16748698
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)646-8646
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	16176468000
<b>Email:</b>	gmccool@wolfgreenfield.com, jcurtis@wolfgreenfield.com
<b>Correspondent Name:</b>	GABRIEL J. MCCOOL
<b>Address Line 1:</b>	WOLF GREENFIELD & SACKS, P.C.
<b>Address Line 2:</b>	600 ATLANTIC AVENUE
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02210-2211
<b>ATTORNEY DOCKET NUMBER:</b>	E0601.70007US00
<b>NAME OF SUBMITTER:</b>	JESSICA H CURTIS
<b>SIGNATURE:</b>	/Jessica H Curtis/

<b>DATE SIGNED:</b>	01/28/2022
---------------------	------------

**Total Attachments: 8**

- source=E060170007US00-ASI\_2-GJM#page1.tif
- source=E060170007US00-ASI\_2-GJM#page2.tif
- source=E060170007US00-ASI\_2-GJM#page3.tif
- source=E060170007US00-ASI\_2-GJM#page4.tif
- source=E060170007US00-ASI\_2-GJM#page5.tif
- source=E060170007US00-ASI\_2-GJM#page6.tif
- source=E060170007US00-ASI\_2-GJM#page7.tif
- source=E060170007US00-ASI\_2-GJM#page8.tif

## ASSIGNMENT OF INVENTION & PATENT RIGHTS

### Parties

- (1) **SCHAEFER, SEBASTIAN** of 315C Tanjong Katong Road, Singapore 437098, Singapore (the “**Inventor**”);
- (2) **NATIONAL HEART CENTRE OF SINGAPORE** a company incorporated under the laws of Singapore with CRN/UEN: 199801148C whose registered office is at 31 Third Hospital Avenue, #03-03 Bowyer Block, Singapore 168753 (“**NHCS**”); and
- (3) **NATIONAL UNIVERSITY OF SINGAPORE** a company incorporated under the laws of Singapore, with CRN/UEN: 200604346E and whose registered office is at 21 Lower Kent Ridge Road, 119077 Singapore (“**NUS**”);  
Each of NHCS and NUS an “**Employer**” or together the “**Employers**” as the context may indicate; and
- (4) **SINGAPORE HEALTH SERVICES PTE LTD** incorporated and registered in Singapore with CRN/UEN: 200002698Z and whose registered office is at 31 Third Hospital Avenue, #03-03, Bowyer Block C. 168753 Singapore, Singapore (“**SingHealth**”).

### Background

- A. The Inventor and the Employers believe that, either by operation of law, Intellectual Property Policy or by virtue of an agreement entered into by the Inventor and the Employers before the making of the Invention, the Employers were, at the time the Invention was made, jointly entitled to an equal share in the property in the contributions of the Inventor to the Invention.
- B. NHCS is a wholly-owned subsidiary of SingHealth and under the intra-group governance documents, including the Intellectual Property Policy of the SingHealth healthcare group, NHCS has agreed, at SingHealth’s demand, to assign its share in the Invention and the Patent Applications to SingHealth.
- C. In order to ensure, and to provide documentary evidence that NUS and SingHealth are the joint owners of the legal and beneficial interest in all the rights, title and interest in, to and arising from the Invention and the Patent Applications, the parties have agreed to execute this Assignment.

### AGREED TERMS

#### 1. Definitions

The definitions in this clause apply in this Assignment.

“**Invention**” means the invention entitled TREATMENT OF HEPATOTOXICITY being the subject matter of the Priority Applications.

**“Patent Applications”** means the Priority Application and any future applications claiming priority from the Priority Application and all matter contained in such future applications, including (without limitation):

- (a) international, national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications; and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

**“Priority Application”** means the priority patent application, short particulars of which are set out in Part 1 of the Schedule.

## 2. Assignment

In consideration of the sum of S\$ 1 SGD (sufficiency and receipt of which the Inventor, the Employers and SingHealth expressly acknowledge), the Inventor hereby assigns jointly and absolutely to the Employers and thereafter, NHCS assigns absolutely to SingHealth, all its right, title and interest in all countries, regions and territories of the world in, to and arising from the Invention and, with effect from immediately prior to the filing of each, the Patent Applications, including (but not limited to):

- (a) in respect of the Invention and any invention that shall be disclosed in, and all matter that shall be contained in, any of the Patent Applications, the right to file applications, claim priority from such applications, and prosecute and obtain grant of patent or other intellectual property protection in respect of any country, region or territory in the world;
- (b) in respect of each and any Patent Application:
  - (i) the right to claim priority from and to prosecute and obtain grant of patents; and
  - (ii) the right to file divisional applications based on the Patent Applications and to prosecute and obtain grant of patent on each and any such divisional application;
- (c) the right to extend to, or register in or in respect of any country, region or territory in the world, each and any of the Patent Applications and to extend to or register in, or in respect of, any country, region or territory in the world any patent or other intellectual property protection granted on any of such applications;
- (d) the absolute entitlement to any patents granted pursuant to any Patent Applications; and
- (e) the right to bring, make, oppose or defend claims or actions, appeal proceedings and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Inventions and the Patent Applications, whether occurring before on or after the date of this Assignment.

**3. Further assurance**

The Inventor shall, at the shared cost of NUS and SingHealth, perform all further acts and things, and execute all further documents, required by law or which NUS and SingHealth request to vest in NUS and SingHealth the full benefit of the right, title and interest assigned to NUS and SingHealth under this Assignment, including (but not limited to):

- (a) documents required to be signed by or on behalf of the Inventor or NUS or SingHealth in the course of any applications which relate to the Invention or to any inventions that shall be disclosed in any of the Patent Applications;
- (b) registration of NUS and SingHealth as joint applicants for, or joint proprietors of, the Patent Applications; and
- (c) assisting NUS and SingHealth in obtaining, defending and enforcing any of the Patent Applications, and assisting with any other proceedings which may be brought by or against NUS and/or SingHealth by or against any third party, or in the resolution of any question concerning the Invention, or the Patent Applications or any inventions that shall be disclosed in any of the Patent Applications.

**4. Right to amend the Schedule**

The Inventor, NHCS, NUS and SingHealth grant the firm of Mewburn Ellis LLP the right to insert in Part 2 of the Schedule to this Assignment any further identification of any existing or future patent applications in any countries, regions or territories of the world, which shall fall within the scope of clause 2 above, or as may be necessary or desirable in order to comply with the rules of a patent office for the recordal of this Assignment.

**5. Counterparts**

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute an original of this Assignment, but all the counterparts shall together constitute the same agreement.

**6. Governing law and jurisdiction**

This Assignment is governed by the laws of the Republic of Singapore and is subject to the exclusive jurisdiction of its courts.

**Schedule: The Patent Applications****Part 1: Priority Applications**

Country	Application No.	Application Date	Title
GB	1915003.6	17 October 2019	TREATMENT OF HEPATOTOXICITY

**Part 2: Identification of some, but not necessarily all, patent applications falling within the scope of clause 2 of this Assignment**

Country/region	Application No.	Application Date	Title	Signature for Mewburn Ellis LLP

Executed by SEBASTIAN SCHAEFER  
in the presence of:

  
SIGNATURE OF INVENTOR

  
SIGNATURE OF WITNESS

NAME: Prof. Stuart A Cook  
ADDRESS: 6 Sunset Square  
597304 Singapore  
Singapore  
OCCUPATION: Professor  
DATE: 21.11.2019

Executed by NATIONAL HEART  
CENTRE OF SINGAPORE acting by

Prof Terrance CHUA  
Medical Director  
National Heart Centre Singapore

  
SIGNATURE OF AN AUTHORISED  
REPRESENTATIVE

an authorised representative, in the  
presence of:

  
SIGNATURE OF WITNESS

NAME: Madeline Chee  
Executive  
Research Administration &  
Development Office (RA/DO)  
National Heart Centre Singapore

5 Hospital Drive, NHC  
S169609

OCCUPATION:

DATE: 25 NOV 2019



Executed by NATIONAL UNIVERSITY  
OF SINGAPORE acting by

Thomas M. COFFMAN M.B.  
Dean  
Duke-NUS Medical School



SIGNATURE OF AN AUTHORISED  
REPRESENTATIVE

\_\_\_\_\_  
An authorised representative, in the  
presence of:

Rishu Srivastava

\_\_\_\_\_  
SIGNATURE OF WITNESS

NAME: Rishu Srivastava

ADDRESS: Duke-NUS, 8 college Road

OCCUPATION: Technology Development Manager

DATE: 21/11/2019

Executed by SINGAPORE HEALTH SERVICES PTE LTD acting by

ENNY KIESWORD  
Chief Operating Officer, Research  
SINGAPORE HEALTH SERVICES PTE LTD

  
\_\_\_\_\_  
SIGNATURE OF A DIRECTOR

.....  
a director, in the presence of:



\_\_\_\_\_  
SIGNATURE OF WITNESS

NAME: *Chole Chus*

Office of Research  
Singapore Health Services Pte Ltd  
ADDRESS: 20 College Road  
The Academics, Discovery Tower, Level 7  
Singapore 169858  
UEN No. 200002898Z

OCCUPATION: *Senior Exec, SingHealth IP*

DATE: *3 Dec 2019*